Re: Some Questions about MRKR's Immuno Approach
I’m not sure I understand your friends remarks. T-cell therapy such as Car-T approaches are new to medicine. They’ve certainly not been around for 30 years. Additionally Marker is using an approach that targets known antigens on the cancers they are attempting to treat. This is from the FDA clinical trials website
“The investigators will grow T cells from patients' stem cell donors in the laboratory in a way that will train them to recognize the tumor proteins WT1, NY-ESO-1, PRAME, and Survivin, which are expressed on most AML and MDS cancer cells. The cells will be infused at least 30 days post-allogeneic stem cell transplant. In this study, the investigators want see whether these cells will be able to recognize and kill cancer cells that express these proteins. These donor-derived multiTAA-specific T cells are an investigational product not yet approved by the U.S. Food and Drug Administration”
I would think your letter to IR will provide a response that directs you to literature or trials. I doubt they have the time to debate the science. Good luck with your research.